louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04857554: Effects of Sugar-free Products With Added Sweeteners on Glycemic Responses
Official title: Effects of Sugar-free Products With Added Sweeteners: Apricot Jam, Cranberry Cereal Bar, and Cocoa Drink on Glycemic Responses: Randomized Clinical Trial in Healthy Humans
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Potential Abnormality of Glucose Tolerance
Appetitive Behavior
Keywords: blood glucose
glycemic index
cereal bar
jam
cocoa
Lead sponsor: Agricultural University of Athens
Sponsor class: OTHER
First posted: 2021-04-23
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Crossover Assignment
Primary purpose: OTHER

Brief summary: This study investigated the effects of three commonly used sugar-free snacks with added sweeteners on glycemic responses

Detailed description: This study aimed at 1. to determine the glycemic index and glycemic load of three sugar-free products with added sweeteners: apricot jam, cranberry cereal bar, and cocoa drink, and 2. to investigate the effects of these products on the postprandial glycemic response in healthy subjects

Eligibility criteria: Inclusion Criteria:

* healthy
* non-smoking
* non-diabetic men and women
* body mass index (BMI) between 18 and 29.9 kg/m2

Exclusion Criteria:

* severe chronic disease (e.g. coronary heart disease, diabetes mellitus,kidney or liver conditions, endocrine conditions)
* gastrointestinal disorders
* pregnancy
* lactation
* competitive sports
* alcohol
* drug dependency

Primary outcomes:
measure: Capillary blood glucose responses
timeFrame: 2 hours
Secondary outcomes:
measure: Subjective appetite ratings
timeFrame: 2 hours
Other outcomes:
Locations:
city: Athens
country: Greece
facility: Agricultural University of Athens
state: Attica
Study officials:
affiliation: Agricultural University of Athens
name: Aimilia Papakonstantinou, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01818154: Validation of a New Hand Held Light Emitting Diode Device for the Determination of Minimal Erythema Dose (MED)
Official title: Validation of a New Hand Held Light Emitting Diode (LED) Device for the Determination of Minimal Erythema Dose (MED) for Narrowband Ultraviolet B.
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Phototherapy
Keywords: phototherapy
light emitting diode
minimal erythema dose
narrowband UVB
Lead sponsor: Henry Ford Health System
Sponsor class: OTHER
First posted: 2013-03-26
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 120
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: OTHER

Brief summary: The purpose of this study is to validate a new hand held light emitting diode (LED) device for the measurement of minimal erythema dose (MED) for narrow band Ultraviolet B (UVB) radiation by comparing to the traditional approach of measurement of the minimal erythema dose.


Eligibility criteria: Inclusion Criteria:

1. Age greater than 18 years.

Exclusion Criteria:

1. Pregnancy
2. Lactation
3. History of photosensitivity disorder
4. Photosensitizing medications
5. Personal history of melanoma or non-melanoma skin cancer.
6. Skin disease on the back

Primary outcomes:
measure: Minimal Erythema Dose
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Detroit
country: United States
facility: Henry Ford Medical Center Department of Dermatology
state: Michigan
Study officials:
affiliation: Henry Ford Dermatology
name: Iltefat H Hamzavi, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04403854: Structural Problems in Brainstem and Cervical Spine Cord in ME/CFS
Official title: The ME-SH (Myalgic Encephalomyelitis in Stockholm-Harvard) Study: Structural Problems in Brainstem and Cervical Spine Cord in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome(ME/CFS) - a Case-control Study
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Chronic Fatigue Syndrome
Lead sponsor: Bragee Clinics
Sponsor class: OTHER
First posted: 2020-05-27
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Diagnoses with ME/CFS and healthy controls

Brief summary: A case control study on patients with ME/CFS and healthy controls on prevalence of cervical obstructions, Cerebro spinal fluid (CSF) pressure and laboratory findings.

Detailed description: 50 patients and 50 healthy controls will undergo clinical exams and blood test of inflammatory and other findings as well as magnetic resonance imaging (MRI) with spectroscopy. The patients will undergo csf -sampling and measurements of CSF pressure.

Eligibility criteria: Inclusion Criteria:

Diagnose Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) according to Canada Consensus Criteria from 2003

Exclusion Criteria:

Bleeding abnormality Contraindication to Magnetic Resonance Imaging MRI Pregnancy

Primary outcomes:
measure: Prevalance of cervical obstructions
timeFrame: Two days
measure: Prevalence of Intracranial Hypertension
timeFrame: Two days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Medect Clinical Trials
name: Björn Bragee, MD
role: STUDY_CHAIR
References:
Clinical trial NCT04299854: Modality of Induction of Labor in Obese Women at Term (MODOBAT)
Official title: Modalités de Déclenchement Des Patientes Obèses à Terme (MODOBAT)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Induction of Labor Affected Fetus / Newborn
Obese
Keywords: Induction of Labor
BMI
Obesity
caesarean
C-section
Pregnancy
Balloon
Dinoprostone
Lead sponsor: Centre Hospitalier Universitaire de Besancon
Sponsor class: OTHER
Collaborators: name: Hopital Nord Franche-Comte
First posted: 2020-03-09
Enrollment: 77
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients of the level III maternity of university hospital center of Besançon and level IIB maternity of regional hospital of Trevenans, France.

Brief summary: In normal-weight patients, numerous studies show an equivalence of efficacy between dinoprostone and balloon to induce labor. In obese patients, this efficacy is not known, although inductions of labor are more frequent. MODOBAT aims to describe the ability to obtain a vaginal delivery of two modality of induction of labor (vaginal dinoprostone and single balloon Foley catheter) in obese women at term.

Detailed description: Obesity has for several decades become a global epidemic in developed countries. In case of pregnancy, obesity leads to an increased risk of obstetric complications, the indications of induction of labor are then more frequent. Unfortunately the rate of failed induction is also higher and therefore the risk of caesarean section is increased in obese women compared to normal-weight patients when induction of labor is indicated. However, in this context effectiveness of each mode of induction is not known. Some retrospective studies would suggest that the balloon would be more effective because it would not be affected by the increase in fat mass but this result are not , but the to confirm this hypothesis.

The aim of this study is to describe the caesarean section rate in induction of labor by vaginal dinoprostone and single balloon Foley catheter in obese women. Patients in the vaginal dinoprostone arm will be included retrospectively and patients in the single balloon Foley catheter arm will be included prospectively.

Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years
* Medical indication of induction of labor
* BMI ≥ 30 kg / m2
* Bishop \< 6
* Singleton
* Gestational age \> 36 SA + 6j
* Cephalic presentation

Exclusion Criteria:

* Adults under guardianship or curatorship
* Scarred uterus
* Placenta praevia

Primary outcomes:
measure: Cesarean sections
timeFrame: 1 year
Secondary outcomes:
measure: Entry into active phase (dilation to 5-6 cm)
timeFrame: 1 year
measure: Complication
timeFrame: 1 year
Other outcomes:
Locations:
city: Besançon
country: France
facility: CHU Besançon
city: Trévenans
country: France
facility: Hopital Nord Franche-Comté
Study officials:
References:
Clinical trial NCT00211354: Treatment of Retinal Vein Occlusion (RVO) With Open-Label Anecortave Acetate (15mg.)
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Retinal Vein Occlusion
Lead sponsor: Manhattan Eye, Ear & Throat Hospital
Sponsor class: OTHER
Collaborators: name: Alcon Research
First posted: 2005-09-21
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Retinal Vein Occlusion is a blockage of the blood vessels that drain out of the retina. Complications of retinal vein occlusion which threaten vision include neovascularization(growth of new blood vessels)and macular edema ( accumulation of fluid "leaking" from abnormal blood vessels). Currently, the treatment of retinal vein occlusion is laser photocoagulation. This treatment has found to have limited use in this type of condition.Anecortave Acetate is being considered as an attempt to control the growth of the abnormal blood vessels.


Eligibility criteria: Inclusion Criteria:

1. Clinical diagnosis of patients Retinal Vein Occlusion.
2. Patients must be 18 years of age or older to receive treatment.
3. Visual acuity of 20/30 to 20/320 Study Eye on the ETDRS visual acuity chart.
4. Visual acuity of 20/800 or better Fellow Eye on the ETDRS visual acuity chart.

Exclusion Criteria:

1. Patient with significantly compromised visual acuity in the study eye due to concomitant ocular conditions.
2. Patients who have undergone intraocular surgery within last 2 months.
3. Patient participating in any other investigational drug study.
4. Use of an investigational drug or treatment related or unrelated to their condition within 30 days prior to receipt of study medication.
5. Inability to obtain photographs to document CNV (including difficulty with venous access).
6. Patient with significant liver disease or uremia.
7. Patient with known adverse reaction to fluorescein and indocyanine green or iodine.
8. Patient has a history of any medical condition which would preclude scheduled visits or completion of study.
9. Patient has had insertion of scleral buckle in the study eye.
10. Patient has received radiation treatment.
11. Patient is on anticoagulant therapy with the exception of aspirin.
12. Patient is pregnant or nursing.

Primary outcomes:
measure: to investigate the use of anecortave acetate for treatment of retinal vein occlusion
timeFrame: 24 months
Secondary outcomes:
measure: mean change of VA (ETDRS) from baseline to 24 months
timeFrame: 24 months
Other outcomes:
Locations:
city: New York
country: United States
facility: Manhattan Eye, Ear & Throat Hospital
state: New York
Study officials:
affiliation: Manhattan Eye, Ear & Throat Hospital
name: Lawrence A. Yannuzzi, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00581854: Phase 2 Hyper-CVAD/Rituximab for Untreated Mantle Cell Lymphoma
Official title: Phase II Pilot Study of Hyper-CVAD Plus Rituximab for Previously Untreated Mantle Cell Lymphoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Mantle Cell Lymphoma
Keywords: untreated mantle cell lymphoma
Lead sponsor: University of Wisconsin, Madison
Sponsor class: OTHER
First posted: 2007-12-28
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: rituximab and modified (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years

Detailed description: rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years

Eligibility criteria: Inclusion Criteria:

* Untreated mantle cell lymphoma

Exclusion Criteria:

* Pregnant or breast feeding

Primary outcomes:
measure: Complete Response Rate to Induction Therapy
timeFrame: Median follow up of 37 months
Secondary outcomes:
Other outcomes:
Locations:
city: Madison
country: United States
facility: UWCCC
state: Wisconsin
Study officials:
affiliation: University of Wisconsin, Madison
name: Brad S Kahl, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kahl BS, Longo WL, Eickhoff JC, Zehnder J, Jones C, Blank J, McFarland T, Bottner W, Rezazedeh H, Werndli J, Bailey HH; Wisconsin Oncology Network. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol. 2006 Sep;17(9):1418-23. doi: 10.1093/annonc/mdl127. Epub 2006 Jun 9.
Clinical trial NCT04507854: Return to Performance Criteria Following Shoulder Instability Surgery in the Athlete.
Official title: Return to Performance Criteria Following Shoulder Instability Surgery in the Athlete.
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Shoulder
Return to Sport
Surgery
Lead sponsor: University of Liege
Sponsor class: OTHER
First posted: 2020-08-11
Enrollment: 80
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: OTHER

Brief summary: The purpose of this study is to determine whether certain criteria for returning to the field can be predictive of a return of the athlete to a level of performance similar to that of before his shoulder injury. In this context, these different criteria will be tested at 6 months in post-surgery while performance monitoring will be carried out at 12, 18 and 24 months.


Eligibility criteria: Inclusion Criteria:

* Athletes playing sports soliciting the upper limb (\> 3 hours per week)
* Athletes between 18 and 35 years of age
* Patients with recent Bankart or Latarjet shoulder surgery (less than 4 months ago)
* Patients accepting the study protocol

Exclusion Criteria:

* Patients with other pathologies that interfere with planned physical activity.

Primary outcomes:
measure: Strength test
timeFrame: 6 months from the surgery
measure: Range of motion
timeFrame: 6 months from the surgery
measure: Functional test
timeFrame: 6 months from the surgery
measure: Questionnaire DASH
timeFrame: 6 months from the surgery
measure: Follow-up questionnaire at 12 months
timeFrame: At 12 months from the surgery
measure: Follow-up questionnaire at 18 months
timeFrame: At 18 months from the surgery
measure: Follow-up questionnaire at 24 months
timeFrame: At 24 months from the surgery
Secondary outcomes:
Other outcomes:
Locations:
city: Liège
country: Belgium
facility: University of Liege
Study officials:
References:
Clinical trial NCT04977154: Prevention in Belgian Hockey : What Does the Staff Really Put in Place?
Official title: Prevention in Belgian Hockey : What Does the Staff Really Put in Place?
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Primary Prevention
Questionnaire and Survey
Hockey Player
Lead sponsor: University of Liege
Sponsor class: OTHER
First posted: 2021-07-26
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Hockey trainer at different level of play

Brief summary: Purpose: To provide an update on the implementation of prevention among hockey players by their entourage.

Materiel and method: This study will be conducted by the means of a questionnaire. The target population consisted of trainers.

The questionnaire will be validated by experts and published on an online survey website


Eligibility criteria: Inclusion Criteria:

* Professions: hockey trainer

Exclusion Criteria:

* /

Primary outcomes:
measure: Primary prevention by a questionnaire
timeFrame: Time Frame: The questionnaire will last 15 minutes at most
Secondary outcomes:
Other outcomes:
Locations:
city: Liège
country: Belgium
facility: University of Liège
Study officials:
References:
Clinical trial NCT06789354: Body Awareness and Perception Across Menstrual Phases:
Official title: Body Awareness and Perception Across Menstrual Phases: A Multidimensional Perspective
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Menstrual Cycle
Keywords: Body Awareness
Menstrual Cycle
Lead sponsor: Marmara University
Sponsor class: OTHER
First posted: 2025-01-23
Enrollment: 147
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Female volunteers aged 18-35 years with regular menstrual cycles (28 ± 2 days) participated in the study,

Brief summary: The study explores the dynamic interplay between body awareness and body perception across the menstrual cycle's phases, emphasizing hormonal influences on these dimensions. Conducted with 43 female participants aged 18-35, this research highlights significant variability in body-related experiences tied to hormonal fluctuations.

The study aims to address the gap in understanding how menstrual cycle phases impact women's body awareness-sensitivity to physiological states-and body perception, encompassing self-image and physical self-evaluation.

Detailed description: Methods: Participants were divided based on menstrual phases: follicular, ovulatory, and luteal. Hormonal fluctuations were tracked through menstrual calendars and ovulation kits. Tools such as the Body Awareness Questionnaire (BAQ) and Multidimensional Body-Self Relations Questionnaire (MBSRQ) assessed participants' awareness and perception. Other assessments included the Premenstrual Syndrome Scale (PMS), Menstruation Attitude Scale (MAS), and physical activity tracking through the IPAQ-SF questionnaire.

Limitations The reliance on self-reported data and single-cycle assessments are noted as constraints, suggesting the need for longitudinal studies for greater robustness.

Eligibility criteria: Inclusion Criteria:

* female volunteers
* aged 18-35 years
* regular menstrual cycles

Exclusion Criteria:

* not using hormonal contraceptives in the preceding six months
* having no history of gynecological disorders
* having no chronic diseases

Primary outcomes:
measure: Body Awareness Questionnaire (BAQ)
timeFrame: through study completion, an average of 1 year
measure: Body Perception Scale (BPS)
timeFrame: through study completion, an average of 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Marmara University
Study officials:
References:
Clinical trial NCT01417754: Changes in Breast 3D Ultrasound Measurements Using Toremifene
Official title: Volume and Circulation Changes of The Breast in 3D Ultrasound During Toremifene Versus Nonmedicated Menstrual Cycle
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Circulatory; Change
Keywords: toremifene
Lead sponsor: Satakunta Central Hospital
Sponsor class: OTHER
Collaborators: name: Tampere University Hospital
name: Tampere University
First posted: 2011-08-16
Enrollment: 20
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: To investigate if there are detectable changes in volume and circulation in breasts of healthy volunteers using toremifene 20 mg in luteal phase of the menstruation cycle versus nonmedicated cycle.

Detailed description: 20 women were participated to this trial.

Eligibility criteria: Inclusion Criteria:

* age 25-45 healthy person
* regular menstrual cycles
* safe contraception(for example sterilization or condom)

Exclusion Criteria:

* gynecological or other type of cancer
* hormonal contraception
* pregnancy

Primary outcomes:
measure: circulation changes of the breast
timeFrame: cycle day 23 to 26
Secondary outcomes:
Other outcomes:
Locations:
city: Pori
country: Finland
facility: Porin Lääkäritalo
Study officials:
affiliation: Satakunta Central Hospital
name: Sinikka Oksa, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Tampere University Hospital
name: Johanna Mäenpää, professor
role: STUDY_DIRECTOR
References:
Clinical trial NCT00936754: Safety and Efficacy of a Single Dose of a Polyphenol-enriched Brown Seaweed Powder in Human
Official title: Safety and Efficacy of a Unique Dose of a Brown Seaweeds Powder Enriched in Polyphenols on Human
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Glycemic Index
Keywords: Glycemic index
Reduction of glycemic index of ingested foods
Lead sponsor: innoVactiv Inc.
Sponsor class: INDUSTRY
First posted: 2009-07-10
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER

Brief summary: The primary endpoint of this trial will be to evaluate the safety of a single administration in human of a dose of 500 mg of a polyphenol-rich algal powder when taken 30 minutes before a test meal. The secondary endpoint of this trial will be to evaluate if a single administration in human of a dose of 500 mg of a polyphenol-rich algal powder is able to reduce the rate of carbohydrate absorption as measured by following postprandial glycemia and insulinemia.


Eligibility criteria: Inclusion Criteria:

* Healthy volunteer
* BMI between 20 and 30
* Non-smoking

Exclusion Criteria:

* Iodine allergy
* Diabetes
* Use of dietary supplements for duration of study
* History of major surgeries or surgeries of the stomach or digestive tract

Primary outcomes:
measure: Safety of a single 500 mg administration of a brown seaweed extract in human
timeFrame: First administration up to 7 days after last administration
Secondary outcomes:
measure: Significant reduction of glycemic index of test food
timeFrame: Immediately after product administration (single use)
measure: Significant reduction in postprandial glycemia
timeFrame: Immediately after product administration (single use)
measure: Significant reduction in postprandial insulinemia
timeFrame: Immediately after product administration (single use)
Other outcomes:
Locations:
city: Quebec
country: Canada
facility: Institut des Nutraceutiques et des Aliments Fonctionnels (INAF)
Study officials:
affiliation: Institut des nutraceutiques et des aliments fonctionnels
name: Patrick Couture, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: